From the aspects of clinical application, enhancement of SRG3 expression in APCs derived from patients by either retroviral gene delivery or chemical treatment can provide another potential way to generate APCs to modulate Th1/Th17-biased immune responses in multiple sclerosis [47]. Here, SMARCC1 is linked to multiple sclerosis.